André Bryskier Clinical Microbiology and Infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Grepafloxacin: microbiological properties

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

The changing epidemiology of severe infections in the ICU

Herpes zoster in non-hospitalized children

Migrant health—a cause for concern?

Atypical respiratory pathogens

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Hydatid disease Clinical Microbiology and Infection

Link between intracellular pathogens and cardiovascular diseases

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

A. Bryskier Clinical Microbiology and Infection

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

Inga Odenholt, Elisabeth Löwdin, Otto Cars

The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci Keith Klugman, Fred Goldstein,

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

Pharmacodynamic properties of HMR 3004, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time.

Cephalosporins: a pharmacological update

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Ventilator-associated pneumonia—Understanding epidemiology and pathogenesis to guide prevention and empiric therapy Patrick Francioli, Jean Chastre,

Sepsis and neutropenia induced by clozapine

Uncommon opportunistic fungi: new nosocomial threats

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease Inge O. Baas, G. Johan A. Offerhaus, Ralph.

A. Bryskier Clinical Microbiology and Infection

A. Bryskier Clinical Microbiology and Infection

Antibacterial drug discovery in the 21st century

Community-acquired pneumonia: epidemiologic and clinical consideration

Grepafloxacin: pharmacokinetics and tissue penetration

Training in infectious diseases and tropical medicine in Britain

Reducing antibiotic use in influenza: challenges and rewards

Definition of the Clinical Antibacterial Spectrum of Activity

Clinical infection services—the Leiden experience

Ethan Rubinstein, Itzhak Levy Clinical Microbiology and Infection

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Empiric therapy of bacterial infections in severe neutropenia

Overview of cefixime use in community-acquired infections

Sanford Chodosh Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

G.C. Schito Clinical Microbiology and Infection

Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3- ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant.

Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: a consensus statement by a working party Dilip Nathwani, Christopher Conlon Clinical.

The future of diagnostic bacteriology

Vincent Calvez, Marc Grandadam Clinical Microbiology and Infection

Presentation transcript:

New concepts in the field of cephalosporins: C-3' quaternary ammonium cephems (Group IV) André Bryskier Clinical Microbiology and Infection Volume 3, Pages S1-S6 (April 1997) DOI: 10.1111/j.1469-0691.1997.tb00642.x Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Structure of C-3' quaternary ammonium cephems Clinical Microbiology and Infection 1997 3, S1-S6DOI: (10.1111/j.1469-0691.1997.tb00642.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Structure of dianionic and zwitterionic cephalosporins Clinical Microbiology and Infection 1997 3, S1-S6DOI: (10.1111/j.1469-0691.1997.tb00642.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 Structure of C-3' and C-7 quaternary ammonium cephems. Clinical Microbiology and Infection 1997 3, S1-S6DOI: (10.1111/j.1469-0691.1997.tb00642.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 Activity of C-3' quaternary ammonium cephems against P. aeruginosa. From Le Noc et al. 18. Clinical Microbiology and Infection 1997 3, S1-S6DOI: (10.1111/j.1469-0691.1997.tb00642.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 5 Activity of C-3' quaternary ammonium cephems against S. pneumoniae. From Frémaux et al. 19. Clinical Microbiology and Infection 1997 3, S1-S6DOI: (10.1111/j.1469-0691.1997.tb00642.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 6 Activity of C-3' quaternary ammonium cephems against S. aureus. From Le Noc et al. 18. Clinical Microbiology and Infection 1997 3, S1-S6DOI: (10.1111/j.1469-0691.1997.tb00642.x) Copyright © 1997 European Society of Clinical Infectious Diseases Terms and Conditions